Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive symbols : Virx save search
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma
Published: 2024-04-15 (Crawled : 12:00) - globenewswire.com
VIRX | $0.8363 -1.36% -1.33% 55K
|
Manufacturing
|
| O: -12.71%
H: 0.97%
C: -24.27%
t-cell positive topline trial therapeutics results
Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose Levels
Published: 2023-12-04 (Crawled : 13:30) - globenewswire.com
VIRX | $0.8363 -1.36% -1.33% 55K
|
Manufacturing
|
| O: -1.84%
H: 11.23%
C: -2.96%
tumors tumor trial therapeutics show
Viracta Therapeutics Announces Publication in Blood Advances Demonstrating Promising and Durable Signal of Nana-val Efficacy in Patients with Relapsed or Refractory (R/R) Epstein-Barr Virus-Positive (EBV+) Lymphoma
Published: 2023-08-08 (Crawled : 12:00) - globenewswire.com
VIRX | $0.8363 -1.36% -1.33% 55K
|
Manufacturing
|
| O: 0.71%
H: 5.67%
C: 2.13%
publication blood therapeutics
Viracta Therapeutics’ Pivotal NAVAL-1 Trial Achieves Efficacy Threshold for Expansion in Relapsed or Refractory EBV-positive Peripheral T-Cell Lymphoma (R/R EBV+ PTCL)
Published: 2023-06-28 (Crawled : 12:00) - globenewswire.com
VIRX | $0.8363 -1.36% -1.33% 55K
|
Manufacturing
|
| O: 1.4%
H: 8.91%
C: 4.14%
t-cell expansion trial
Viracta Therapeutics Announces First Clinical Response in Epstein-Barr Virus-Positive (EBV+) Solid Tumor Setting and Outlines Key 2023 Clinical Objectives
Published: 2023-01-08 (Crawled : 20:20) - globenewswire.com
VIRX | $0.8363 -1.36% -1.33% 55K
|
Manufacturing
|
| O: 17.07%
H: 8.33%
C: 5.21%
tumor therapeutics response
Viracta Therapeutics Announces Preliminary Dose-Ranging Data from the Phase 1b/2 Trial of Nana-val in Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors at the ESMO Immuno-Oncology Congress
Published: 2022-11-30 (Crawled : 00:00) - globenewswire.com
VIRX | $0.8363 -1.36% -1.33% 55K
|
Manufacturing
|
| O: 1.29%
H: 0.85%
C: -4.26%
trial therapeutics tumors phase 2b
Viracta Therapeutics Provides an Update on the Phase 1b/2 Trial of Nana-val in Patients with Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors and Announces Upcoming Poster Presentation at the ASCO Annual Meeting
Published: 2022-06-02 (Crawled : 13:00) - biospace.com/
VIRX | $0.8363 -1.36% -1.33% 55K
|
Manufacturing
|
| O: 0.0%
H: 3.33%
C: 2.86%
trial therapeutics presentation asco phase 2b
Viracta Therapeutics to Host Key Opinion Leader Webinar on Nana-val for the Treatment of Advanced Epstein-Barr Virus-Positive Solid Tumors
Published: 2022-04-20 (Crawled : 17:00) - biospace.com/
VIRX | $0.8363 -1.36% -1.33% 55K
|
Manufacturing
|
| O: 0.48%
H: 2.53%
C: -2.85%
treatment therapeutics
Viracta Therapeutics Announces First Patient Dosed in Phase 1b/2 Trial of Nana-val in Patients with Advanced Epstein-Barr Virus-Positive Solid Tumors
Published: 2022-01-31 (Crawled : 14:00) - biospace.com/
VIRX | $0.8363 -1.36% -1.33% 55K
|
Manufacturing
|
| O: 0.0%
H: 13.69%
C: 11.2%
solid tumors phase 1b trial therapeutics phase 1 positive phase 2b
Viracta Therapeutics Announces Final Phase 1b/2 Data Showing Promising and Durable Signal of Efficacy for Nana-val in Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma in an Oral Presentation at ASH 2021
Published: 2021-12-13 (Crawled : 20:00) - biospace.com/
VIRX | $0.8363 -1.36% -1.33% 55K
|
Manufacturing
|
| O: -2.86%
H: 0.0%
C: 0.0%
phase 1b therapeutics presentation phase 1 positive phase 2b
Viracta Therapeutics Announces Orphan Drug Designation Granted by FDA for its All-Oral Combination of Nanatinostat and Valganciclovir (Nana-val) for the Treatment of Epstein Barr Virus-Positive Diffuse Large B-cell Lymphoma
Published: 2021-11-29 (Crawled : 14:00) - biospace.com/
VIRX | $0.8363 -1.36% -1.33% 55K
|
Manufacturing
|
| O: 3.57%
H: 4.21%
C: -12.45%
treatment fda drug granted therapeutics orphan drug positive t-cell designation
Viracta Therapeutics Initiates Phase 1b/2 Trial in Epstein-Barr Virus-Positive (EBV+) Solid Tumors
Published: 2021-10-06 (Crawled : 12:15) - prnewswire.com
VIRX | $0.8363 -1.36% -1.33% 55K
|
Manufacturing
|
| O: -1.69%
H: 3.18%
C: 0.27%
solid tumors phase 1 positive trial phase 1b phase 2b
Viracta Therapeutics Announces FDA Clearance of IND Application for Phase 1b/2 Trial in Epstein-Barr Virus-Positive (EBV+) Solid Tumors
Published: 2021-07-21 (Crawled : 14:00) - biospace.com/
VIRX | $0.8363 -1.36% -1.33% 55K
|
Manufacturing
|
| O: 1.34%
H: 2.64%
C: 0.26%
fda clearance fda solid tumors phase 1 positive trial phase 1b clearance phase 2b
Viracta Therapeutics Announces the Initiation of NAVAL-1, a Global Pivotal Trial for the Treatment of Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma
Published: 2021-06-01 (Crawled : 14:00) - biospace.com/
VIRX | $0.8363 -1.36% -1.33% 55K
|
Manufacturing
|
| O: -3.66%
H: 6.3%
C: -0.9%
treatment positive trial
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
BOF | $2.08 77.78% 39.06% 110M
|
BHIL | $0.1793 -4.37% 19.24% 340K
|
Agriculture, Forestry, Fishing ...
UMAC | $1.48 -1.33% 14.87% 20K
|
CI | $352.28 -0.11% 13.53% 2
|
Health Services
CIG.C | $2.89 -1.37% 12.8% 2.3K
|
n/a
MTH | $154.69 -2.21% 12.68% 450K
|
Consumer Durables
BMTX 4 | $1.545 0.98% 10.03% 2.5K
|
Information
TAL | $12.26 0.57% 9.22% 12M
|
Consumer Services
ASXC | $0.243 -2.41% 7.0% 1.1M
|
Manufacturing
IHT P | $1.3712 0.82% 6.48% 0
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.